AUS
NZ
UK
CA
USA
IND
Technology One Limited
Technology One Limited (ASX:TNE) is based in Fortitude Valley and engaged in the research, development, marketing and sale of integrated enterprise business software solutions across New Zealand, Australia and other countries worldwide. On March 23rd, 2019, the TNE stock closed the market trading at AUD 8.010, down 1.11% and quite close to the 52-week high of AUD 8.180. Over the past few months, the stock has performed reasonably well with the return yields for three months at 36.59% and for six months at 51.90%.
The company serves clients across multiple sectors including local government, education, health and community services, asset and project intensive industries as well as corporates and financial services.
Recently, Technology One appointed Mr Clifford Rosenberg as an independent, Non-Executive Director. The company released its 2018 Annual Report posting the net profit before tax at $ 66.5 million, up 15% on $ 58 million recorded in FY2017 and an increase in annual license fees by 16% to $ 140 million from $ 120 million in FY2017. Besides, the total annual recurring revenue exhibited growth of 22% from $ 138.6 million in the prior year to $ 168.6 million.
Also, in light of the strong performance and confidence in the coming year, the Board declared a dividend of 6.16 cents per share for the second half of FY2018, up 10% on the prior year and a special dividend of 2 cents per share. This takes the annual dividend to 11.02 cents per share, up 8% on FY2017 and a payout ratio of 68%.
Pro Medicus Limited
The Richmond, Australia-based Pro Medicus Limited (ASX:PME) is a healthcare IT company that offers enterprise imaging and radiology information systems (RIS) software to hospitals, diagnostic imaging groups, and other allied entities worldwide. The company has a valuation of above AUD 1.7 billion. On March 22nd, the PME stock ended the market trading at the price of AUD 17.220, up 1.29% and very close to the 52-week high of AUD 17.70 recorded on March 20th, 2019.
The stockâs YTD return also stands positive at 49.49%. Besides, it has generated a three-month return yield of 52.03% and a six-month return yield of 45.78%.
Recently, Pro Medicus released its Investor Presentation March 2019. For the half-year ended December 31st, 2019 (H1 FY2019), the profit after tax rose by 184.3% to $ 9.082 million along with the underlying NPAT also improving by 79.9% to $ 9.234 million on the prior corresponding period. The company also recorded an EBIT margin of 51.8%. For the period, a fully-franked dividend of $ 0.035 per share with a special advance dividend of $ 0.025 per share was paid out.
During the half-year, the company expanded its project pipeline as it signed a new $ 5-million contract with Carle in Illinois, US; a $ 27-million deal with Boston-based Partners Healthcare and received contract extensions amongst others. The net cash and cash equivalents as of December 31st, 2018 amounted to $ 24.73 million.
Disclaimer
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.
